Final ProgramCPSA 2012
Transforming Drug Discovery & Development Through Innovation:
Past, Present and Future
October 1 - 4, 2012
Sheraton Bucks County Hotel
Langhorne, PA
Session Synopsis
Wednesday, 10:15 am - 11:45 am
Bridging the Gap Between Pharmacokinetics and Pharmacodynamics
Through Quantitative LC-MS
Discussion Leader: Lucinda Cohen, Merck
This session will focus on novel approaches leveraging LC-MS methodologies for not just drug exposure and pharmacokinetics purposes but also measurement of efficacy readouts including biomarkers and diagnostics in preclinical and clinical settings. Four distinguished speakers from various pharmaceutical companies will present diverse case studies showcasing their science in both success and failure. The gamut of innovative analytical tools will be presented, from liquid handling automation to chromatographic methods and mass spectrometry magic.
Presentations:
Ultra-Sensitive Cytokine Quantitation in Serum and Tissues by Immunoaffinity nano-LC-MS/MS
Joe Palandra, Pfizer
Strategies to Augment and Troubleshoot Ligand Binding Assays with Fit-For-Purpose LC/MS/MS Methodology: Case Studies
Erick Kindt, Pfizer
Title TBA
Bernard Choi, Merck
Focusing on Core Analytical Capabilities to Support an Expanding Need for Clinical Biomarker Analysis and the Development of Companion Diagnostics
Brad Ackermann, Eli Lilly and Company
Return to program